EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic

E M G Olthof, C A Aitken, A G Siebers, F J van Kemenade, I M C M de Kok

Public Health · 2024

DOI: 10.1016/j.puhe.2023.11.026 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Public Health, 2024. Verfasst von E M G Olthof und 4 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC University Medical Center Rotterdam, Department of Public Health, Rotterdam, the Netherlands. Electronic address: e.olthof@erasmusmc.nl. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Resilience, Psychological, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Organisation of a screening programme influences programme resilience to a disruption as COVID-19. Due to COVID-19, the Dutch human papillomavirus-based cervical screening programme was temporarily suspended. Afterwards, multiple measures have been taken to catch-up participation. This study aimed to investigate programme resilience by examining the effect of COVID-19 and programme measures taken on participation in cervical screening. STUDY DESIGN: Observational cohort study. METHODS: Data from the national screening registry and Dutch nationwide pathology databank (Palga) were used on invitations and follow-up in 2018/2019 (pre-COVID) and 2020 (COVID). Sending invitations, reminders and self-sampling kits were suspended from March to July 2020. Main outcome measures include distribution of participant characteristics (age, region and screening history), participation rates by age and region, time between invitation and participation (i.e. response time) and self-sampling use per month. RESULTS: Participation rate was significantly lower in 2020 (49.8%) compared to 2018/19 (56.8%, P < 0.001), in all ages and regions. Compared to 2018/19, participation rates decreased most in women invited from January to March 2020 (-6.7%, -9.1% and -10.4%, respectively). From August, participation rates started to recover (difference between -0.8% and -2.7%). Median response time was longer in February and March (2020: 143 and 173 days; 2018/19: 53 and 55 days) and comparable from July onwards (median difference 0-6 days). Self-sampling use was higher in 2020 (16.3%) compared to 2018/19 (7.6%). CONCLUSIONS: The pandemic impacted participation rates in the Dutch cervical screening programme, especially of women invited before the programme pause. Implementation of self-sampling in national cervical screening programmes could increase participation rates and could serve as an alternative screening method in times of exceptional health care circumstances, such as a pandemic. Due to the well-organised programme and measures taken to catch-up participation, the impact of COVID-19 on the screening programme remained small.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsResilience, PsychologicalCOVID-19HumansFemalePandemicsEarly Detection of CancerVaginal SmearsMass ScreeningPapillomaviridae

Stichwörter der Autor:innen

COVID-19Cervical cancer screeningHPV screeningResilienceSelf-samplingSuspension

Autor:innen und Institutionen

  • Erasmus MC University Medical Center Rotterdam, Department of Public Health, Rotterdam, the Netherlands. Electronic address: e.olthof@erasmusmc.nl.
  • Erasmus MC University Medical Center Rotterdam, Department of Public Health, Rotterdam, the Netherlands; Erasmus MC University Medical Center Rotterdam, Department of Pathology, Rotterdam, the Netherlands.
  • The Dutch Nationwide Pathology Databank (PALGA Foundation), Houten, the Netherlands.
  • Erasmus MC University Medical Center Rotterdam, Department of Pathology, Rotterdam, the Netherlands.
  • Erasmus MC University Medical Center Rotterdam, Department of Public Health, Rotterdam, the Netherlands.

Zitieren

APA

Olthof, E. M. G., Aitken, C. A., Siebers, A. G., van Kemenade, F. J., & de Kok, I. M. C. M. (2024). Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic. Public Health. https://doi.org/10.1016/j.puhe.2023.11.026

Vancouver

Olthof EMG, Aitken CA, Siebers AG, van Kemenade FJ, de Kok IMCM. Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic. Public Health. 2024. doi:10.1016/j.puhe.2023.11.026

BibTeX
@article{Olthof2024,
  author = {Olthof, E M G and Aitken, C A and Siebers, A G and van Kemenade, F J and de Kok, I M C M},
  title = {Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic},
  journal = {Public Health},
  year = {2024},
  doi = {10.1016/j.puhe.2023.11.026}
}
Kostenlos starten →